Product Liability Lawyer Blog
Depo-Provera (depot medroxyprogesterone acetate, often shortened to DMPA) has been used for decades as an injectable form of birth control. For many patients, it’s been prescribed for convenience and reliability. In 2026, however, Depo-Provera is also at the center of rapidly evolving product-liability litigation focused on allegations that repeated/long-term use may be associated with an increased risk of meningioma, a typically noncancerous intracranial tumor that can still cause serious neurological harm.
Our Depo-Provera lawsuit claims attorneys explain what has changed recently, what plaintiffs are alleging, how these cases are evaluated, and what documentation tends to matter most when investigating a potential claim. This article is written for patients and families, not for other lawyers, so it focuses on practical realities rather than legal jargon.
What changed recently is that the U.S. label now includes a meningioma warning
A major development driving 2026 claim volume is the FDA-approved label language that now explicitly addresses meningioma. The Depo-Provera CI prescribing information, updated in late 2025, includes language instructing clinicians to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera if a meningioma is diagnosed.
That label language matters for two reasons. First, it changes the informed-consent conversation between prescribers and patients. Second, it intensifies litigation disputes over what the manufacturer knew, when it knew it, and whether earlier warnings were adequate.
It’s also important to maintain perspective: professional organizations that counsel clinicians and patients have emphasized that even when studies show an increased relative risk, the absolute risk for any individual patient may still be low. ACOG’s patient counseling material notes that the overall risk remains small while acknowledging study findings that prompted discussion and counseling updates.
The science people point to in 2026: what the studies generally say (without overclaiming)
Most Depo-Provera lawsuits are grounded in observational research that reports an association between certain progestogens and intracranial meningioma risk, especially with prolonged exposure. A large French national study published in The BMJ reported an increased risk of intracranial meningioma with prolonged use of medroxyprogesterone acetate and certain other progestogens.
More recently, U.S.-based observational work has also examined DMPA exposure and meningioma diagnosis, reporting higher relative risk, particularly with longer exposures, while also noting that the number needed to harm suggests low clinical risk overall.
A careful point here: these studies are often discussed in headlines as proof, but scientifically, they’re typically about association and risk patterns. Litigation then focuses on whether the totality of evidence, biological plausibility, and regulatory history support the legal claim that warnings were inadequate.
The lawsuits: what people are claiming and where the cases are centralized
The main allegation is a classic product-liability theory: failure to warn. Plaintiffs typically claim that Depo-Provera’s manufacturer did not adequately warn prescribers and patients about the risk of meningioma, particularly for long-term or repeated administration. That better warnings would have changed prescribing decisions, monitoring, and patient choices.
Many federal cases have been centralized in a multidistrict litigation (MDL) proceeding: In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, in the Northern District of Florida. The court maintains a public docket page and posts orders by date, reflecting ongoing case management, pilot case schedules, and briefing on key issues.
A key contested issue you’ll see referenced in credible reporting is preemption, the defense argument that federal labeling law can bar certain state-law failure-to-warn claims, depending on what the FDA did or did not allow at different times. Reuters has covered Pfizer’s preemption arguments and the court’s use of pilot cases to move core issues forward.
What injuries are commonly discussed in Depo-Provera claim evaluations
Meningiomas can be slow-growing and may be discovered after months or years of symptoms, or incidentally on imaging. In claim evaluations, the focus is typically not just on whether a tumor exists, but on the real-world consequences: neurological symptoms, need for surgery, radiation, seizure management, visual changes, cognitive effects, and long-term limitations.
From a legal standpoint, a viable claim usually needs more than a diagnosis. It needs a documented course that shows the injury was clinically significant and resulted in measurable damages—medical costs, lost income, impairment, and life impact.
How product-liability lawyers typically analyze a Depo-Provera case
Even though every case is fact-specific, most evaluations revolve around a few core questions.
The first question is proof of use. Depo-Provera is often administered in clinics, so pharmacy records alone may not capture the full injection history. The strongest cases usually include clinic administration notes, injection logs, EOBs, or chart documentation showing frequency and duration of use.
The second question is proof of diagnosis and causation, and ready documentation. For meningioma claims, this usually means MRI/CT imaging reports, neurosurgery consults, operative reports if surgery occurred, pathology reports if tissue was removed, and follow-up records documenting symptoms and outcomes.
The third question is timing and duration. Many of the studies and the label discussion emphasize repeated or prolonged exposure. Duration isn’t the only factor, but it tends to be a central one in screening.
The fourth question is about damages. Product cases are built around harm. That includes medical expenses, time out of work, long-term restrictions, and pain and suffering. In serious cases, it can include future care planning, neurocognitive testing, vocational limitations, and caregiver burden.
Documentation that tends to matter most and why patients should gather it early
When people try to pull records months later, they often discover that injection documentation is scattered: one OB/GYN office, one community clinic, maybe periods of care in different states. The easiest way to strengthen an evaluation is to gather documentation while it’s still accessible.
For the Depo-Provera use history, the gold records are the provider’s administrative records and chart notes. For diagnosis, the gold records are radiology reports and specialist notes, plus operative and pathology records when applicable. For damages, work absence documentation, disability paperwork, and a clear treatment chronology can be decisive.
If you only have partial records, that doesn’t automatically end the conversation, but it usually means more work is required to reconstruct the timeline.
Common misconceptions that hurt Depo-Provera claims
One misconception is that “a new warning automatically proves a past case.” It doesn’t. A label update can be important evidence, but courts and juries still look at what was known when, whether warnings were adequate under the standards at the time, and whether the plaintiff can prove causation and damages.
Another misconception is that any meningioma equals a case. In reality, claim viability often depends on duration of use, the medical record, the clinical significance of the tumor, alternative risk factors, and the damages.
A third misconception is that MDL means quick payout. MDLs are designed to coordinate discovery and rulings; they can accelerate some aspects and slow others. What the MDL does provide is structure, pilot cases, expert challenges, and a framework that may influence settlement posture over time.
Don’t stop or switch contraception without speaking to your clinician
If you are currently using Depo-Provera and have concerns, treat this as a medical counseling issue first. The FDA label language focuses on monitoring and discontinuation upon diagnosis, and professional guidance emphasizes individualized risk counseling. Your prescribing clinician is the right person to discuss your personal risk factors and alternatives.
Talk to Jeffrey Glassman Injury Lawyers about a Depo-Provera injury claim
If you were diagnosed with a meningioma after Depo-Provera use and you’re wondering whether you may have a viable product liability claim, an early case review can help clarify the path forward and preserve key records.
Call (617) 777-7777 for a free consultation. We’ll review your Depo-Provera use history, medical documentation, and damage picture, and we’ll explain how the MDL and any Massachusetts-specific issues may affect your options.